Efficacy trials of Rift Valley Fever vaccines and therapeutics - Guidance on clinical trial design

Overview

On 1 November 2019, WHO convened members of the R&D Blueprint working group on clinical trial design with RVF experts as well as national representatives from affected countries to discuss the science of vaccine and treatment evaluation for RVF and agree on principles on how to determine whether or not RVF therapeutic and vaccine strategies are safe and effective in humans.

Deliberations were informed by key clinical and epidemiological considerations, also recognizing the critical knowledge gaps that well-designed clinical and epidemiological studies could help address to better inform the development of RVF therapeutics and vaccines.